
|Videos|June 13, 2017
ASCO 2017: Updates on HER2-Positive Breast Cancer Treatment
Author(s)Karen Gelmon, MD
This video highlights the latest studies presented at the 2017 ASCO Annual Meeting on the treatment of HER2-positive breast cancer.
Advertisement
In this video, Karen Gelmon, MD, of the British Columbia Cancer Agency in Canada, highlights the latest studies on the treatment of HER2-positive breast cancer presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
Gelmon chaired an education session at the meeting on the optimal management of early and advanced HER2-positive breast cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab Yields High pCR Rate in Desmoplastic Melanoma
2
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
3
Reducing Secondary Diagnostic Delay Through the Breast Clinical Reporting and Data System
4
Fecal Microbiota Transplantation Shows Feasibility in Metastatic RCC
5
































